The historical rank and industry rank for ExpreS2ion Biotech Holding AB's Net Margin % or its related term are showing as below:
FRA:5JD0'
s Net Margin % Range Over the Past 10 Years
Min: -2331.99 Med: -481.03 Max: -100.41
Current: -1077.46
FRA:5JD0's Net Margin % is ranked worse than 79.49% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:5JD0: -1077.46
ExpreS2ion Biotech Holding AB (FRA:5JD0) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ExpreS2ion Biotech Holding AB Net Margin % Related Terms
ExpreS2ion Biotech Holding AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5JD0 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a Net Margin % of -927.08% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on ExpreS2ion Biotech Holding AB and its competitors. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #752 out of 946 companies in the Biotechnology industry, placing it in the top 79.5%.
Is ExpreS2ion Biotech Holding AB's Net Margin % too high?
ExpreS2ion Biotech Holding AB's current Net Margin % is -927.08%. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #752 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #752 out of 946 companies for Net Margin %. This places ExpreS2ion Biotech Holding AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Net Margin % is -927.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
ExpreS2ion Biotech Holding AB (FRA:5JD0) has a current Net Margin % of -927.08%. The stock's GF Value™ is €0.08, compared to a current price of €0.04 — trading 53.5% below its estimated fair value. The current Net Margin % is -927.08%. ExpreS2ion Biotech Holding AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (FRA:5JD0), the current Net Margin % is -927.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (FRA:5JD0) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of €0.04 is trading 53.5% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:5JD0:
Net Margin %: -927.08%
GF Value™: €0.08 vs. price of €0.04 (53.5% below fair value)
No single metric tells the full story. See the FRA:5JD0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB Business Description
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
41GF Score
Get the complete analysis for FRA:5JD0
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5JD0 has been successfully added to your 
